Key result
Metabolic syndrome is linked to a higher prevalence of LVH and CHD.
Why the study?
Obesity and metabolic syndrome are rising public health problems in Europe, and their role in the development of coronary heart disease requires further characterization.
Cohort (n=4,627)
No
Metabolic syndrome is associated with a higher prevalence of left ventricular hypertrophy and coronary heart disease, highlighting the importance of its management in cardiovascular disease prevention.
Metabolic syndrome was associated with higher LVH and CHD prevalence; leaves open causal role and need for prospective trials.
Obesity, a component of the metabolic syndrome, is a rising public health problem, continuously increasing in the European countries. The therapeutic success of the patient with metabolic syndrome requires a multidisciplinary approach to lifestyle changes, weight loss, continuous and dynamic dietary improvement, sedentary reduction, normalization of blood pressure, glycemia and lipid parameters. We performed a retrospective study that was conducted in the Clinical Rehabilitation Hospital in Iasi, with 4627 patients that were admitted in the Cardiovascular Rehabilitation Clinic from January 2011 to December 2015 with the diagnosis of metabolic syndrome according to WHO definition (Group 1) or with other comorbidities (Group 2). In the first group were included 1064 patients diagnosed with metabolic syndrome. This group has predominantly smoking female patients. Also, in group 1 were diagnosed more patients with left ventricular hypertrophy and coronary heart disease compared to group 2. Most of the patients with inflammatory syndrome were included in the group without metabolic syndrome (group 2). The results of our study confirm that metabolic syndrome is a cluster of abnormalities whose evolution determines the development of coronary heart disease. All this would advocate for treating metabolic syndrome as the primary method of preventing cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Maștaleru et al. (2018) conducted a cohort in Metabolic syndrome (n=4,627). Metabolic syndrome vs. Other comorbidities (without metabolic syndrome) was evaluated on Left ventricular hypertrophy and coronary heart disease. Among 4,627 patients, the 1,064 individuals with metabolic syndrome had a higher prevalence of left ventricular hypertrophy and coronary heart disease compared to those without.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: